Metastatic Gastric Adenocarcinoma Recruiting Phase 2 Trials for Rivoceranib (DB14765)

Also known as: Adenocarcinoma gastric / Adenocarcinoma of stomach (disorder)

IndicationStatusPhase
DBCOND0074521 (Metastatic Gastric Adenocarcinoma)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04781686Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric CancerTreatment